Intuitive Surgical, Inc. (NASDAQ:ISRG) Position Cut by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. trimmed its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 19.9% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 26,366 shares of the medical equipment provider’s stock after selling 6,567 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in Intuitive Surgical were worth $11,729,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Kovack Advisors Inc. raised its stake in shares of Intuitive Surgical by 29.2% during the fourth quarter. Kovack Advisors Inc. now owns 1,350 shares of the medical equipment provider’s stock valued at $455,000 after purchasing an additional 305 shares in the last quarter. Legacy Capital Wealth Partners LLC bought a new stake in shares of Intuitive Surgical during the fourth quarter valued at about $275,000. Gilbert & Cook Inc. raised its stake in shares of Intuitive Surgical by 6.5% during the fourth quarter. Gilbert & Cook Inc. now owns 3,437 shares of the medical equipment provider’s stock valued at $1,160,000 after purchasing an additional 211 shares in the last quarter. Mather Group LLC. raised its stake in shares of Intuitive Surgical by 4.7% during the fourth quarter. Mather Group LLC. now owns 1,685 shares of the medical equipment provider’s stock valued at $568,000 after purchasing an additional 76 shares in the last quarter. Finally, Choreo LLC raised its stake in shares of Intuitive Surgical by 98.1% during the fourth quarter. Choreo LLC now owns 2,015 shares of the medical equipment provider’s stock valued at $680,000 after purchasing an additional 998 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ISRG has been the topic of a number of research analyst reports. JPMorgan Chase & Co. lifted their target price on Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. Robert W. Baird lifted their target price on Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a report on Friday, July 19th. Truist Financial lifted their target price on Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. Citigroup lifted their target price on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Finally, The Goldman Sachs Group initiated coverage on Intuitive Surgical in a report on Thursday, May 30th. They set a “buy” rating and a $500.00 target price on the stock. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Intuitive Surgical presently has an average rating of “Moderate Buy” and a consensus target price of $444.70.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG traded up $3.16 during trading hours on Tuesday, hitting $482.35. 845,221 shares of the stock were exchanged, compared to its average volume of 1,530,504. The firm has a market capitalization of $171.09 billion, a P/E ratio of 87.07, a P/E/G ratio of 4.97 and a beta of 1.39. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $493.97. The company’s 50 day moving average is $450.50 and its 200 day moving average is $412.03.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm’s revenue was up 14.5% compared to the same quarter last year. During the same period last year, the business posted $1.18 earnings per share. Research analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In other news, Director Amal M. Johnson sold 2,943 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the completion of the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Amal M. Johnson sold 2,943 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the completion of the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the transaction, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The disclosure for this sale can be found here. Insiders sold a total of 55,364 shares of company stock valued at $26,191,001 in the last ninety days. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.